When will the newest Alzheimer's medicine be available to patients in Switzerland (and how to get it sooner)?
Blog
-
January 09, 2025Read more »
-
January 09, 2025Read more »
Is the new Alzheimer's medicine available to Swiss patients, and how can you get it?
-
January 09, 2025Read more »
A new efficient and safe medicine to lower triglycerides in FCS patients is now available. But when will it be available to you?
-
December 11, 2024Read more »
When will the first approved medicine for fatty liver with fibrosis be available in Europe and the UK?
-
December 10, 2024Read more »
When will the new medicine for COPD be available to patients in Europe and the UK (and how not to wait)?
-
December 04, 2024Read more »
When will the first targeted therapy for CLDN 18.2-positive gastric and GEJ cancer be available to patients in Europe?
-
November 28, 2024Read more »
When will the first targeted therapy for acute leukemia with KMT2A translocation be available outside the USA?
-
November 28, 2024Read more »
When will the first medicine for NPC be available to patients in Europe, the UK, and beyond (and how not to wait)?
-
November 12, 2024Read more »
When is the first targeted therapy for HER2-expressing BTC getting its approval? All about the timelines and your options in the meantime.
-
June 26, 2023Read more »
All the safe and legal options to access Leqembi while it's waiting for its EU approval.
-
Read more »
Here is an overview of each medicine to help guide you and your physician when making a treatment decision for Cystic Fibrosis:
-
September 02, 2019Read more »
Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.
-
August 29, 2019Read more »
Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.
-
August 16, 2019Read more »
Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.
-
August 15, 2019Read more »
Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.
-
Read more »
New skin cancer medicine now approved in the EU for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.
-
Read more »
Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.
-
April 24, 2019Read more »
Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.
-
February 28, 2019Read more »
Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years.
-
February 25, 2019Read more »
A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.
-
February 05, 2019Read more »
Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.
-
January 30, 2019Read more »
Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).
-
January 14, 2019Read more »
New medicine shows statistically significant improvements for prostate cancer patients.
-
December 03, 2018Read more »
Australia provides reimbursement for cystic fibrosis medicine.
-
November 30, 2018Read more »
The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.
-
October 03, 2018
-
Read more »
According to study investigators, about a third of patients could benefit from this therapy that may offer remissions, relieve symptoms and save lives. -
August 02, 2018Read more »
2018 has been a good year for new cancer treatments says the U.S. AACR.
-
August 02, 2018Read more »
Kisqali is now the only CDK4/6 inhibitor for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US. -
Read more »
The approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome.
Recent Posts
